论文部分内容阅读
目的:探究美莎拉嗪辅助治疗溃疡性结肠炎的临床疗效。方法:选取2013年3月~2016年3月期间,我院接受治疗的76例溃疡性结肠炎患者作为研究对象,按照治疗药物的不同分为观察组(n=38)和对照组(n=38),对照组采用柳氮磺胺吡啶治疗,观察组在对照组的基础上采用美莎拉嗪治疗,观察分析两组患者的治疗效果,不良反应发生率,炎症指标改善情况和治疗前后DAI评分。结果:观察组患者的治疗效果总有效率(94.73%)高于对照组患者的治疗效果总有效率(63.15%),不良反应发生率(5.26%)低于对照组患者的不良反应发生率(23.68%),炎症指标改善情况好于对照组,治疗后的DAI评分低于对照组,两组患者治疗效果,不良反应发生率,炎症指标改善情况和DAI评分具有一定的差异(P<0.05),统计学意义显著。结论:采用美莎拉嗪联合柳氮磺胺吡啶对溃疡性结肠炎患者进行治疗具有较大的意义。
Objective: To investigate the clinical effect of methadzine adjuvant treatment of ulcerative colitis. Methods: A total of 76 patients with ulcerative colitis treated in our hospital from March 2013 to March 2016 were selected as study subjects and divided into observation group (n = 38) and control group (n = 38). The control group was treated with sulfasalazine. The observation group was treated with metasalzine on the basis of the control group. The therapeutic effect, the incidence of adverse reactions, the improvement of inflammation index and the DAI score before and after treatment were observed and analyzed in the two groups . Results: The total effective rate (94.73%) in the observation group was higher than that in the control group (63.15%) and the adverse reaction rate (5.26%) was lower than that in the control group ( 23.68%). The improvement of inflammation index was better than that of the control group. After treatment, the DAI score was lower than that of the control group. There was a significant difference between the two groups in the treatment effect, incidence of adverse reactions, improvement of inflammation index and DAI score (P <0.05) , Statistically significant. Conclusion: The use of mesalazine combined with sulfasalazine for the treatment of patients with ulcerative colitis is of great significance.